We are live on ! Find out more
CYTK icon

Cytokinetics
CYTK

134 hedge funds and large institutions have $502M invested in Cytokinetics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 70 increasing their positions, 23 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

671% more call options, than puts

Call options by funds: $7.07M | Put options by funds: $917K

204% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 23

55% more capital invested

Capital invested by funds: $324M → $502M (+$178M)

4.5% more ownership

Funds ownership: 72.87% → 77.37% (+4.5%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3% less funds holding

Funds holding: 138 → 134 (-4)

11% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 18

Holders
134
Holders Change
-4
Holders Change %
-2.9%
% of All Funds
2.91%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
70
Reduced
23
Closed
18
Calls
$7.07M
Puts
$917K
Net Calls
+$6.15M
Net Calls Change
+$5.98M

Top Buyers

1
DCM
Driehaus Capital Management
Illinois
+$21.1M
2
BI
BVF Inc
California
+$13.3M
3
Millennium Management
Millennium Management
New York
+$10M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.85M
5
State Street
State Street
Massachusetts
+$3.61M

Top Sellers

1
LPU
Lansdowne Partners (UK)
United Kingdom
-$11.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.49M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.78M
4
SDIC
South Dakota Investment Council
South Dakota
-$1.65M
5
Goldman Sachs
Goldman Sachs
New York
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$102M +$1.88M +195,445 +2%
BI
2
BVF Inc
California
$58.2M +$13.3M +1,375,061 +36%
Vanguard Group
3
Vanguard Group
Pennsylvania
$44.6M +$1.43M +147,849 +4%
WA
4
Wasatch Advisors
Utah
$36.2M +$274K +28,385 +0.9%
State Street
5
State Street
Massachusetts
$27.2M +$3.61M +374,437 +18%
DCM
6
Driehaus Capital Management
Illinois
$24.6M +$21.1M +2,187,614 New
Millennium Management
7
Millennium Management
New York
$22.1M +$10M +1,040,133 +113%
FCMI
8
Foresite Capital Management IV
California
$21.4M +$1.7M +175,800 +10%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$18.8M -$2.49M -258,129 -13%
OM
10
Opaleye Management
Massachusetts
$10.1M +$482K +50,000 +6%
RM
11
RP Management
New York
$9.85M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$8.48M +$800K +82,998 +12%
Northern Trust
13
Northern Trust
Illinois
$7.62M +$1.28M +133,189 +24%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$7.23M +$456K +47,339 +8%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$6.83M +$5.85M +607,000 New
PA
16
Pinnacle Associates
New York
$6.15M -$518K -53,742 -9%
DCM
17
DAFNA Capital Management
California
$5.37M +$742K +76,902 +19%
Principal Financial Group
18
Principal Financial Group
Iowa
$5.21M +$225K +23,282 +5%
Renaissance Technologies
19
Renaissance Technologies
New York
$4.14M +$897K +93,000 +34%
Invesco
20
Invesco
Georgia
$3.94M -$1.18M -122,396 -26%
Charles Schwab
21
Charles Schwab
California
$3.71M +$372K +38,606 +13%
Ameriprise
22
Ameriprise
Minnesota
$3.63M +$108K +11,210 +4%
SDIC
23
South Dakota Investment Council
South Dakota
$3.4M -$1.65M -170,994 -36%
Morgan Stanley
24
Morgan Stanley
New York
$3.22M +$1.9M +196,786 +220%
Two Sigma Investments
25
Two Sigma Investments
New York
$3.02M -$1.14M -118,197 -31%
1
2 3 4 5

CYTK Hedge Fund Activity: Q2 2019 in Review

134 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2019, worth a combined $502M — up 55% from $324M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CYTK and 16 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 70 added.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $21.1M. The largest seller was Lansdowne Partners (UK), exiting entirely with an estimated $11.8M sold.

  • 134 institutional investors held Cytokinetics (CYTK) as of Q2 2019, down from 138 in Q1 2019.
  • Funds reported $502M of Cytokinetics stock for Q2 2019, up 55% quarter-over-quarter.
  • 16 funds opened new Cytokinetics positions in Q2 2019 and 18 closed out, a net change of -2 holders.
  • The largest Cytokinetics buyer in Q2 2019 was Driehaus Capital Management, an estimated $21.1M added.
  • The largest Cytokinetics seller in Q2 2019 was Lansdowne Partners (UK), an estimated $11.8M sold.

Based on aggregated 13F filings for Q2 2019.